Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975

被引:147
作者
Efficace, F.
Bottomley, A.
Smit, E. F.
Lianes, P.
Legrand, C.
Debruyne, C.
Schramel, F.
Smit, H. J.
Gaafar, R.
Biesma, B.
Manegold, C.
Coens, C.
Giaccone, G.
Van Meerbeeck, J.
机构
[1] European Org Res Treatment Canc, Ctr Data, Qual Life Unit, B-1200 Brussels, Belgium
[2] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[3] Hosp Mataro, Mataro, Spain
[4] St Antonius Hosp, Nieuwegein, Netherlands
[5] Rijnstate Hosp Arnhem, Arnhem, Netherlands
[6] Natl Canc Inst, Cairo, Egypt
[7] Jeroen Bosch Ziekenhuis sHertogenbosch, Shertogenbosch, Netherlands
[8] Univ Med Ctr, Mannheim, Germany
[9] Univ Hosp, Ghent, Belgium
关键词
lung cancer; prognostic factor; quality of life; survival;
D O I
10.1093/annonc/mdl183
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this prognostic factor analysis was to investigate if a patient's self-reported health-related quality of life (HRQOL) provided independent prognostic information for survival in non-small cell lung cancer (NSCLC) patients. Patients and methods: Pretreatment HRQOL was measured in 391 advanced NSCLC patients using the EORTC QLQ-C30 and the EORTC Lung Cancer module (QLQ-LC13). The Cox proportional hazards regression model was used for both univariate and multivariate analyses of survival. In addition, a bootstrap validation technique was used to assess the stability of the outcomes. Results: The final multivariate Cox regression model retained four parameters as independent prognostic factors for survival: male gender with a hazard ratio (HR) = 1.32 (95% CI 1.03-1.69; P = 0.03); performance status (0 to 1 versus 2) with HR = 1.63 (95% CI 1.04-2.54; P = 0.032); patient's self-reported score of pain with HR= 1.11 (95% CI 1.07-1.16; P < 0.001) and dysphagia with HR = 1.12 (95% CI 1.04-1.21; P = 0.003). A 10-point shift worse in the scale measuring pain and dysphagia translated into an 11% and 12% increased in the likelihood of death respectively. A risk group categorization was also developed. Conclusion: The results suggest that patients' self-reported HRQOL provide independent prognostic information for survival. This finding supports the collection of such data in routine clinical practice.
引用
收藏
页码:1698 / 1704
页数:7
相关论文
共 29 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[3]  
AUGUSTIN NH, 2002, 76 FREIB CTR DAT AN
[4]   THE EORTC QLQ-LC13 - A MODULAR SUPPLEMENT TO THE EORTC CORE QUALITY-OF-LIFE QUESTIONNAIRE (QLQ-C30) FOR USE IN LUNG-CANCER CLINICAL-TRIALS [J].
BERGMAN, B ;
AARONSON, NK ;
AHMEDZAI, S ;
KAASA, S ;
SULLIVAN, M .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (05) :635-642
[5]   Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer [J].
Brown, J ;
Thorpe, H ;
Napp, V ;
Fairlamb, DJ ;
Gower, NH ;
Milroy, R ;
Parmar, MKB ;
Rudd, RM ;
Spiro, SG ;
Stephens, RJ ;
Waller, D ;
West, P ;
Peake, MD .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7417-7427
[6]   Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients [J].
Chiarion-Sileni, V ;
Del Bianco, P ;
De Salvo, GL ;
Lo Re, G ;
Romanini, A ;
Labianca, R ;
Nortilli, R ;
Corgna, E ;
Dalla Palma, M ;
Lo Presti, G ;
Ridolfi, R .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (11) :1577-1585
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]  
Cull A, 2002, EORTC quality of life group translation procedure
[9]   Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial [J].
Dancey, J ;
Shepherd, FA ;
Gralla, RJ ;
Kim, YS .
LUNG CANCER, 2004, 43 (02) :183-194
[10]   Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? [J].
Efficace, F ;
Bottomley, A ;
Coens, C ;
Van Steen, K ;
Conroy, T ;
Schöffski, P ;
Schmoll, H ;
Van Cutsem, E ;
Köhne, CH .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (01) :42-49